Science Advances

Supplementary Materials

The PDF file includes:

  • Fig. S1. Protein characterization of DRAs.
  • Fig. S2. Cytotoxicity dose-response curves for TRAIL and DRA in nine human CRC cell lines and three patient-derived cell lines.
  • Fig. S3. There is no difference between mRNA expression levels of genes associated with apoptosis in TRAIL-sensitive and TRAIL-resistant cell lines.
  • Fig. S4. DRA monotherapy and combination of DRA with sensitizer drugs are selectively proapoptotic in human cancer cells, sparing normal cells.
  • Fig. S5. Subcutaneously injected ELPdepot-DRA formulation is as efficacious as intratumoral injection for in vivo tumor growth inhibition.
  • Fig. S6. Palbociclib combination with A-1331852 results in unacceptable toxicity in nude mice.
  • Fig. S7. Cell viability assay of single-agent sensitizers in CRC247 cells and combination synergy plot.
  • Fig. S8. Combination of DRA with XIAP and BCL-XL inhibitors is well tolerated in vivo in nude mice implanted with PDX.
  • Legend for table S1
  • Table S2. Summary of RKO cell viability results from the combination of DRA with small-molecule sensitizers informed from top hits of the knockout screen.
  • Table S3. Flow cytometry data for RKO treatment with drug combinations.

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Screen results for TRAIL and DRA in RKO cells.

Files in this Data Supplement: